Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer. Lilly has been bolstering its pipeline through small deals as its cancer therapy Alimta faces fierce competition from copycat versions while betting on potential blockbuster drug tirzepatide, or Mounjaro, to drive growth. Point Biopharma is currently testing radioligand therapy candidates, PNT2002 and PNT2003, in late-stage studies.